ASN: Caffeine Associated With Reduced Mortality in CKD
FRIDAY, Nov. 3, 2017 -- Caffeine consumption appears to have a dose-dependent protective effect against mortality in chronic kidney disease (CKD) patients, according to a study presented at the annual meeting of the American Society of Nephrology, being held Oct. 31 to Nov. 5 in New Orleans.
Miguel Bigotte Vieira, M.D., from the Centro Hospitalar Lisboa Norte in Portugal, and colleagues examined the association between caffeine consumption and mortality among 2,328 patients with CKD in a prospective cohort study using data from the National Health and Nutrition Examination Survey (1999 to 2010).
The researchers found a dose-dependent inverse association between caffeine and all-cause mortality. Compared with individuals in the first quartile of caffeine consumption, those in the second, third, and fourth quartiles had adjusted hazard ratios for mortality of 0.88 (95 percent confidence, 0.68 to 1.44), 0.78 (95 percent confidence, 0.6 to 1.01), and 0.76 (95 percent confidence, 0.59 to 0.97), respectively (P = 0.027 for trend across quartiles). This association was independent of confounding variables including age, gender, race, annual family income, education level, estimated glomerular filtration rate, albumin/creatinine ratio, hypertension, smoking status, dyslipidemia, body mass index, previous cardiovascular events, and diet.
"These results suggest that advising patients with CKD to drink more caffeine may reduce their mortality," Vieira said in a statement. "This would represent a simple, clinically beneficial, and inexpensive option, though this benefit should ideally be confirmed in a randomized clinical trial."
© 2020 HealthDay. All rights reserved.
Posted: November 2017
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.